SERENA-6 Trial Explores New Treatment for Endocrine Resistance in Metastatic Breast Cancer
The SERENA-6 trial, a randomized, double-blind, placebo-controlled study, is investigating the efficacy of camizestrant in patients with hormone receptor-positive metastatic breast cancer (HR+ mBC) who develop ESR1 mutations (ESR1m) during first-line treatment with aromatase inhibitors (AI) and CDK4/6 inhibitors. The trial aims to determine if switching to camizestrant, an oral selective estrogen receptor degrader (SERD), can extend progression-free survival (PFS) compared to continuing the standard AI and CDK4/6i therapy. The study's design is notable for its use of circulating tumor DNA (ctDNA) to guide treatment decisions, allowing for a personalized approach to therapy. Initial results suggest that camizestrant may offer clinical benefits by targeting ESR1m, a common mechanism of resistance in HR+ mBC. 
